NASDAQ:NXTC - NextCure Stock Price, Forecast & News

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure Inc (NASDAQ:NXTC) posted its earnings results on Tuesday, November, 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.02. The firm had revenue of $1.58 million for the quarter, compared to analysts' expectations of $1.50 million. View NextCure's Earnings History.

NextCure is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for NextCure.

6 analysts have issued 1-year target prices for NextCure's shares. Their forecasts range from $44.00 to $87.00. On average, they anticipate NextCure's share price to reach $66.17 in the next year. This suggests a possible upside of 35.7% from the stock's current price. View Analyst Price Targets for NextCure.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NextCure.

News articles about NXTC stock have been trending negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NextCure earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for NextCure.

NextCure saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,150,000 shares, an increase of 10.6% from the January 15th total of 1,040,000 shares. Based on an average trading volume of 585,000 shares, the short-interest ratio is currently 2.0 days. Approximately 6.4% of the shares of the stock are sold short. View NextCure's Current Options Chain.

Some companies that are related to NextCure include Evotec (EVTCY), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE), Zai Lab (ZLAB), Myokardia (MYOK) and Emergent Biosolutions (EBS).

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Amgen (AMGN), Alibaba Group (BABA), CVS Health (CVS), Honeywell International (HON), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Cisco Systems (CSCO), Home Depot (HD), Procter & Gamble (PG) and NVIDIA (NVDA).

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray acted as the underwriters for the IPO.

NextCure's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Sofinnova Investments Inc. (11.74%), Canaan Partners X LLC (9.91%), Lord Abbett & CO. LLC (6.34%), Alliancebernstein L.P. (4.67%), ArrowMark Colorado Holdings LLC (3.35%) and State Street Corp (1.83%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Institutional Ownership Trends for NextCure.

NXTC stock was sold by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, EAM Global Investors LLC, EAM Investors LLC, UBS Group AG, J. Goldman & Co LP and Bamco Inc. NY. View Insider Buying and Selling for NextCure.

NXTC stock was purchased by a variety of institutional investors in the last quarter, including Canaan Partners X LLC, Lord Abbett & CO. LLC, ArrowMark Colorado Holdings LLC, Alliancebernstein L.P., State Street Corp, Marshall Wace North America L.P., Sofinnova Investments Inc. and FMR LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan. View Insider Buying and Selling for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $48.76.

NextCure has a market capitalization of $1.11 billion. View Additional Information About NextCure.

The official website for NextCure is http://www.nextcure.com/.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]